Furthermore, upregulation of CD14+HLA-DRlow/− MDSCs was correlated with CLL tumor progression and a poor prognosis for CLL patients, and CD14+HLA-DRlow/− MDSCs were significantly correlated with the presence of CD4+ T and CD5+CD19+ cells in CLL patients, which could significantly inhibit the CD4+ T-cell immune response, contributing to CLL cell progression in CLL patients. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.